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ABSTRACT
Objective: To determine whether use of intrapartum
Pethidine pain analgesia increases the risk for
substance use disorder in adult offspring.
Design: Analysis of data from a cohort study.
Setting: Academic hospital in Leiden, the Netherlands.
Participants: 133 cases and 164 control individuals,
aged 18e20 years at follow-up.
Main outcome measure: Incidence of substance use
disorder or use of alcohol and tobacco.
Results: The lifetime use of addictive substances in
children exposed to intrapartum Pethidine analgesia
was 45% of 133 children versus 48% of 164 not-
exposed subjects (adjusted OR¼0.79, 95% CI 0.48 to
1.29). Recent use of alcohol, tobacco and hard drugs
showed no statistical difference either.
Conclusion: Pethidine for labour pain medication
appears not to be associated with substance misuse or
smoking in later life.
INTRODUCTION
Analgesia during labour is common world-
wide. Methods used include barbiturates,
nitrous oxide, opioids, epidural analgesia,
transcutaneous electric nerve stimulation,
psychoprophylaxis and hypnosis. In the
Netherlands, opiates had been used in 7%e
15% of all deliveries between 2000 and 2007,
which is in 15000e30000 mothers a year.
1 In
the 1970s, intramuscular Pethidine was the
most common drug for pain relief during
labour. In recent years, a rise in the use of
epidural or spinal analgesia and in PCA
(patient-controlled analgesia) with very short
acting opiates intravenously is observed.
However, Pethidine is the most commonly
used opioid worldwide because it is cheap
and easy to administer. Concerns have been
raised about its effectiveness and potential
maternal, fetal and neonatal side effects.
2
After parenteral therapy in the mother, the
opiates can be detected in cord blood with
a plasma level of 50% of that of the mother.
After birth, the child is often sleepy and
slightly respiratory depressed for a few
hours.
34
In 1987, the issue of development of
substance use disorders (SUDs) and behav-
ioural problems in the offspring after peri-
natal analgesic medication was addressed.
5
The authors reported ORs of 4.7 compared
with individuals who did not receive perinatal
analgesic drugs. These results were derived
from caseecontrol studies in patients with
SUD.
6e8
The SUD was attributed to the ‘imprinting
hypothesis’ and was ﬁrst published in the
BMJ in 1990 by Jacobson et al.
7 The brain,
when exposed to a noxe during a window in
time before or during birth, could be
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ARTICLE SUMMARY
Article focus
- Research question: does perinatal Pethidine for
labour pain relief lead to substance use disorder
in later life?
- Is it possible to conﬁrm the published data on an
OR of around 5?
- We hypothesise that there is no relationship.
Key messages
- We cannot conﬁrm earlier data on the risk of
substance use disorder after perinatal analgesia.
- We did not ﬁnd a risk for smoking and drinking
alcohol either.
- Perinatal Pethidine analgesia appears not to be
associated with substance misuse in later life.
Strengths and limitations of this study
- This is a well-designed large cohort study on
long-term effects of perinatal Pethidine analgesia.
- The main limitation is the relatively low response
and the possible selective response.
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Open Access Researchaffected permanently by changing neurotransmitter
receptors, synaptogenesis, myelination, proliferation,
apoptosis, migration of neuronal cells or by stunting of
dendrite growth.
9e12 An epidemiological and clinical
study showed that cannabis exposure before birth is
associated with impulsive and psychiatric disorders in
later life.
13 Conﬂicting results have been publishes about
the association of autism spectrum disorders, develop-
mental delay and learning disorders in offspring after
peripartum exposure to analgesics.
14e17
No long-term follow-up study in children born after
opioid use of the mother during pregnancy or after
opioid labour analgesia has been published. A recent
Cochrane Review has been published looking at the
effectiveness and side effects of intrapartum parenteral
opioids.
18 Short-term follow-up studies did not show
sequelae in children in their development up to
5 years.
19e22
We investigated the association between Pethidine
use and the risk on smoking, drinking alcohol or drug
abuse in offspring 20 years after birth.
METHODS
Sample and study design
Power calculation
Considering the prevalence of drug abuse, smoking and
drinking alcohol, we needed 160 participants in each
group. In total, 85 individuals in each group were sufﬁ-
cient to detect an OR of 4.7 or more between the groups
with 80% power and a type I error of 0.05,
7 assuming
a prevalence of major drug abuse in the control group of
5%.
1 Because of the much more frequent use of tobacco
and alcohol, this sample size was sufﬁcient to detect ORs
around two.
Data about lifetime prevalence and recent substance
use are available for Europe
23 and for the Netherlands
24
(table 1).
Identiﬁcation of the cohort variables
After ethical approval by the Medical Ethical Committee
of the Leiden University Medical Center, the birth ﬁles
from the Academic Hospital Leiden from 1986 to 1987
were used to compose two groups of participants: one
cohort with and the other without labour analgesia by
Pethidine. Included were only healthy babies without
congenital anomalies, born at term after an uncompli-
cated delivery and who had not been admitted in the
paediatric ward. Information was available on maternal
characteristics and obstetric history including medica-
tion as well as the postpartum condition of the newborn.
Data collection
After ﬁnding the recent addresses, we were able to send
validated questionnaires about lifetime and recent (last
month) use of cigarettes, alcohol and drugs. The ﬁrst is
the National Drugs Questionnaire as a part of the
Permanent National Life Style Inquiry that is used from
1997 (with computer-assisted personal interviewing or in
case of drug questions with computer-assisted self-inter-
viewing method) that meet with the European Statistics
Code of Practice. The second questionnaire is a vali-
dated questionnaire for young adults about life events,
schooling and behaviour.
25
Analysis
The primary analysis was a comparison of the prevalence
of substance abuse at adult age between the Pethidine-
exposed and not-exposed groups. Subsequently, the
results were compared with the national drug monitor
study that was done in the same period. A multivariate
logistic regression model was used to calculate ORs and
95% CIs for the outcome measures with age, sex, reli-
gion and parental education as potential confounders.
The analyses were performed with SPSS V.11.5 for
Windows (SPSS Inc).
Non-response
Non-responders received a short questionnaire about yes
or no lifetime or recent use of alcohol, smoking and
drugs. The individuals who responded to the short
questionnaire and those who only partially ﬁlled in the
questionnaire were analysed separately.
RESULTS
From a total of 715 deliveries, 91% of the addresses were
found. Of these 651 individuals, 347 (53%) returned the
questionnaires. One hundred and thirty-three partici-
pants with and 164 without Pethidine analgesia could
be fully evaluated (n¼297, 46%). After a second call, 26
individuals with and 24 without Pethidine analgesia
completed the questionnaire and 92 (53 with and 39
without Pethidine) completed the short questionnaire.
All together, 439 children (67% of 651 children) were
analysed. Both the index and the control group showed
the same distribution of age and sex. There were no
differences in the distribution of parental education or
religion (table 2). These were also similar to national
data. The peripartum data of both groups showed no
differences in birth weight, sex and Apgar scores. All
newborns were healthy and none was admitted in the
paediatric ward.
No differences were found in lifetime or recent use of
drugs, alcohol or tobacco use between both groups. The
Table 1 Lifetime prevalence and recent tobacco, alcohol
and drug use in the Netherlands
24
Lifetime
prevalence (%)
Recent use,
last month (%)
Smoking 72 37
Alcohol 90 79
Cannabis 37 17
XTC 6.2 2.2
Amfetamine 5 1.9
Cocaı ¨ne 4.3 1.7
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No evidence that Pethidine increases risk SUDOR for ever drug abuse was 0.79 (95% CI 0.48 to 1.29)
and for recent drug abuse 1.08 (95% CI 0.49 to 2.37). We
also gathered data about alcohol use, cannabis and
smoking during and after secondary school. These data
did not show differences between the groups either, the
adjusted ORs are presented in table 3. In total, 92 chil-
dren responded to the short questionnaire and 50 chil-
dren partially ﬁlled out the standard questionnaire. No
difference was found in lifetime prevalence of smoking,
alcohol and drug abuse between the Pethidine and the
non-Pethidine group independent of the dose that
ranged from 75 to 150 mg. The ORs were all close to
unity, varying between 0.58 and 1.42.
DISCUSSION
This 20-year follow-up study showed that labour anal-
gesia by Pethidine did not signiﬁcantly increase the
risk of SUD in offspring. We found no association for
hard drugs, tranquilisers, hallucinogenics, anabolics or
soft drugs (including tobacco and alcohol use). This is in
line with the results of the study from the Mayo clinics on
the risk of learning disability after exposure to peri-
partum analgesia.
14
The strength of this study is that it is a large, long-term
follow-up study of a healthy cohort of neonates.
We evaluated putative confounders, such as socioeco-
nomic status, sex, religion and parental education, but
did not ﬁnd differences between the index and the
control group. Uncontrolled confounding is always
possible, but in this instance, one would expect these to
lead to spurious positive associations and not to the
absence of an association. Further investigation of
potential confounders could be valuable. Given the
result of the previous studies reporting a ﬁvefold
increased risk, our sample size with a minimal detectable
RR of 2 was conservative. However, this implies that we
could not detect small risk increases. Nevertheless, the
most likely interpretation of our ﬁndings, which exclude
a risk increase of more than 29% of lifetime drug abuse
in children exposed to Pethidine, is the absence of any
association.
The main limitation of the study is the low response
and the possibility of selected response. It is not incon-
ceivable that drug users responded less than others. It is
of some concern that response was lower in the group
exposed during labour (54%) than in those who were
not (42%). Still, if selective response was only associated
to drug use in adult life, one would expect an attenuated
effect but not the absence of any effect. Bias would have
resulted from a differential response related to opioid
use during delivery, irrespective of drug use later in life.
This seems implausible, as most young adults will not be
aware of the analgetic medication of their mothers
during birth. Reassuring for the absence of major bias is
the fact that the non-respondents to the ﬁrst question-
naire, who responded to the second short questionnaire
Table 2 Distribution of parental education or religion
stratiﬁed by Pethidine and no Pethidine groups
Total group
(n[297)
% Pethidine
(n[133)
%N o
Pethidine
(n[164)
Religion
Christian 41.4 39.8 42.7
Other 4.4 6.8 2.4
No 54.2 53.4 54.9
Education
Low 38.4 32.3 43.3
Intermediate 27.9 32.3 24.4
High 33.7 35.3 32.3
Sex
Male 39.4 42.1 37.2
Female 60.6 57.9 62.8
Low. elementary school and vocational education; intermediate,
high school; high, university.
Table 3 Lifetime or recent use of alcohol, tobacco and drugs stratiﬁed by Pethidine and no Pethidine groups
Total group
(n[297)
% Pethidine
(n[133)
% No Pethidine
(n[164) Adjusted OR (95% CI)*
Smoking cigarettes ever 70.4 68.4 72.0 0.84 (0.50 to 1.41)
Smoking cigarettes recent 41.4 40.6 41.5 0.98 (0.61 to 1.58)
Alcohol ever 98.7 98.5 98.8 0.81 (0.10 to 6.23)
Alcohol recent 86.5 86.5 86.6 0.91 (0.45 to 1.81)
Smoking cannabis ever 46.5 45.1 47.6 0.76 (0.46 to 1.24)
Smoking cannabis recent 8.8 9.8 7.9 1.14 (0.50 to 2.63)
XTC ever 10.1 12.0 8.5 1.42 (0.64 to 3.17)
XTC recent 1.0 2.3 0 e
Amphetamine ever 5.4 4.5 6.1 0.66 (0.22 to 1.99)
Amphetamine recent 1.0 0.8 1.2 0.58 (0.05 to 6.61)
Cocaine ever 6.4 6.0 6.7 0.85 (0.32 to 2.29)
Cocaine recent 2.7 2.3 3.0 0.58 (0.12 to 2.68)
Drug abusey ever 46.8 45.9 47.6 0.79 (0.48 to 1.29)
Drug abusey recent 10.1 10.5 9.8 1.08 (0.49 to 2.37)
*Adjusted for age, religion and parental education.
yThis includes cannabis, XTC, Amphetamine and cocaine.
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No evidence that Pethidine increases risk SUDshowed the same negative association for SUD, drinking
and smoking. The non-responders showed an unequal
distribution in sex compared with the responders: 41%
vs 59% male/female ratio.
In this large follow-up study, we cannot conﬁrm the
results of previous studies that parenteral Pethidine for
labour pain relief is associated with SUD in later life.
Because of the above-mentioned limitations, further
research is needed to assess possible associations
between other forms of intrapartum analgesia and SUD.
Author afﬁliations
1Department of Paediatrics, Maasstadziekenhuis, Rotterdam, the Netherlands
2Bouman Mental Health Care, Rotterdam, the Netherlands
3Department of Prevention and Care Netherlands Institute of Applied Sciences
TNO, Leiden, the Netherlands
4Department of Obstetrics, Leiden University Medical Center, Leiden, the
Netherlands
5Department of Clinical Epidemiology, Leiden University Medical Center,
Leiden, the Netherlands
6Department of statistics, Netherlands Institute of Applied Sciences TNO,
Leiden, the Netherlands
7Netherlands Institute for Neuroscience, an Institute of the KNAW, Amsterdam,
the Netherlands
8Central Ofﬁce for Motor Vehicle Driving Testing (CBR), Amsterdam, the
Netherlands
9Bouman Mental Health Care, Rotterdam, the Netherlands
Contributors All authors contributed to the following criteria: (1) substantial
contribution to conception and design, acquisition of data or analysis and
interpretation of data; (2) drafting the article or revising it critically for
important intellectual content and (3) ﬁnal approval of the version to be
published.
Funding This research received no speciﬁc grant from any funding agency in
public, commercial or not-for-proﬁt sectors.
Competing interests None.
Patient consent Obtained.
Ethics approval Ethics approval was provided by Medical Ethical Committee of
the Leiden University Medical Center, the Netherlands.
Provenance and peer review Not commissioned; externally peer reviewed.
Data sharing statement All data are uploaded to the Dryad data repository and
available for any scientist.
REFERENCES
1. The Netherlands Perinatal Registry. http://www.perinatreg.nl/
home_english
2. Bricker L, Lavender T. Parenteral opioids for labour pain relief:
a systematic review. Am J Obstet Gynecol 2002;186(5 Suppl Nature):
S94e109.
3. Thomas H, Asskali F, Vettermann J. Addition of fentanyl to
bupivacainedperidural analgesia in cesarian section. Anaesthesist
1996;45:635e42.
4. Nicolle E, Devillier P, Durand C, et al. Therapeutic monitoring of
nalbuphine: transplacental transfer and estimated pharmacokinetics
in the neonate. Eur J Clin Pharmacol 1996;49:485e9.
5. Jacobson B, Eklund G, Hamberger L, et al. Perinatal origin of adult
self-destructing behaviour. Acta Psychiatr Scand 1987;76:364e71.
6. Jacobson B, Nyberg K, Eklund G, et al. Obstetric pain medication and
eventual adult amphetamine addiction in offspring. Acta Obstet
Gynecol Scand 1988;67:677e82.
7. Jacobson B, Nyberg K, Gro ¨nbladh L, et al. Opiate addiction in adult
offspring through possible imprinting after obstetric treatment. BMJ
1990;30:1067e70.
8. Nyberg K, Buka S, Lipsitt LP. Perinatal medication as a potential risk
factor for adult abuse in a North American cohort. Epidemiology
2000;11:715e16.
9. Tchernitchin AN, Tchernitchin NN, Mena MA, et al. Imprinting:
perinatal exposures cause the development of diseases during the
adult age. Acta Biol Hung 1999;50:425e40.
10. Fernanadez-Ruiz J, Berrendero F, Herna ´ndez ML, et al. The
endogenous cannabinoid system and brain development. Trends
Neurosci 2000;23:14e20.
11. Swaab DF, Boer K, Mirmian M. Functional teratogenic effects of
chemicals on the developing brain. In: Levene MI, Chervenak FA,
eds. Fetal and Neonatal Neurology and Neurosurgery. Toronto:
Churchill Livingstone, 2001:263e77.
12. Ricalde A, Hammer RP. Perinatal opiate treatment delays growth of
cortical dendrites. Neurosci Lett 1990;115:137e43.
13. Spano MS, Ellgren M, Wang X, et al. Prenatal cannabis exposure
increases heroin seeking with allostatic changes in limbic enkefalin
systems in adulthood. Biol Psychiatry 2007;61:554e63.
14. Flick RP, Lee K, Hofer RE, et al. Neuraxial labor analgesia for vaginal
delivery and its effect on childhood learning disabilities. Anaesth
Analg 2011;112:1424e31.
15. Hattori R, Desimaru M, Nagayami I, et al. Autistic and
developmental disorders after general anesthetic delivery. Lancet
1991;337:1357e8.
16. Sun LS. Editorial: labor analgesia and the developing human brain.
Aneasth Analg 2011;112:1265e7.
17. Wong CA, Scavone BM, Peaceman AM, et al. The risk of caesarean
delivery with neuraxial analgesia given early versus late in labor. N
Engl J Med 2005;352:655e65.
18. Ullman R, Smith LA, Burns E, et al. Parenteral opioids for maternal
pain management in labour. Cochrane Database Syst Revi 2010;(9):
CD007396.
19. Kaye K, Elkind L, Goldberg D, et al. Birth outcomes for infants of drug
abusing mothers. N Y State J Med 1989;89:256e61.
20. Doberczak TM, Kandall SR, Friedmann P. Relationship between
maternal methadone dosage, maternal-neonatal methadone levels,
and neonatal withdrawal. Obstet Gynecol 1993;81:936e40.
21. Hagopian GS, Wolfe HM, Sokol RJ, et al. Neonatal outcome
following methadone exposure in utero. J Matern Fetal Med
1996;5:348e54.
22. Thaithumyanon P, Limpongsanurak S, Praisuwanna P, et al.
Perinatal effects of amphetamine and heroin use during pregnancy on
the mother and infant. J Med Assoc Thai 2007;88:1506e13.
23. Jaarverslag over de stand van de drugsproblematiek in de Europese
Unie. Lisbon: E.W.D.D, 2000. ISBN 92-9168-100-8.
24. Trimbos-instituut, Jeugd en riskant gedrag, kerngegevens 1999,
Utrecht: Cf international equivalent, 2000. http://www.espad.org/
espad-reports
25. Stam H, Grootenhuis MA, Last BF. The course of life of survivors of
childhood cancer. Psychooncology 2005;14:227e38.
PAGE fraction trail=4
4 Rodrigues Pereira R, Kanhai H, Rosendaal F, et al. BMJ Open 2012;2:e000719. doi:10.1136/bmjopen-2011-000719
No evidence that Pethidine increases risk SUD